(Adnkronos) - "I linfomi non-Hodgkin rappresentano una malattia molto frequente, con un'incidenza pari a quella del carcinoma alla vescica. Per le forme aggressive, la ricerca offre oggi cure innovative, dalla prima linea a quelle successive. E con il progetto ‘A cura dell’Arte’, gli spazi del reparto si trasformano in luoghi di sollievo e creatività” Lo ha Detto Antonio Pinto, direttore del Dipartimento di Ematologia e Terapie Innovative dell’Istituto nazionale tumori Fondazione Pascale di Napoli , ideatore del progetto che ha coinvolto l’Accademia di Belle Arti di Napoli per decorare gli spazi di degenza accogliendo i suggerimenti dei pazienti.
Category
🗞
NewsTranscript
00:00Lymphomas are, by definition, the tumors of the immune system.
00:11They are divided into two large groups.
00:14Today we are talking about non-logical lymphomas, which represent a very frequent disease.
00:19The images that have the same incidence as the vesicle carcinoma,
00:24are the neoplasia of the lymphatic system, with cell B,
00:28more frequent than ever.
00:30In particular, aggressive lymphomas,
00:33which represent for us a moment of development,
00:38also of innovative cures,
00:40represent the most frequent neoplasia in the field of non-logical lymphomas.
00:45They represent around 30% of all new cases of lymphomas.
00:51For aggressive non-logical lymphomas,
00:53which represent a very heterogeneous category,
00:58it is important that there is as little time as possible
01:01between the formal diagnosis, which must be histological,
01:05and the start of the therapies,
01:06precisely because, unlike another type of lymphoma,
01:10which is called indolent,
01:11they represent neoplasia, which is true,
01:13they are very aggressive clinically,
01:15but in which the healing capacity,
01:18with the most modern therapies, is very high.
01:20Before, we were able to heal,
01:23which is a different concept to cure, of course,
01:26about 55% of patients with old therapies.
01:31Now we have, for a couple of years in Italy,
01:34a very new first-line therapy
01:36based on a new drug called Polatuzumab,
01:40and today we are able to bring the ability to heal
01:44these patients with aggressive lymphomas
01:47almost at 70-75%,
01:50so it is a big step forward in the management of these patients.
01:55The metaphor of the journey is very appropriate,
01:58because in reality you have to imagine
02:00our emergency rooms as wagons of a train,
02:04in which one, not necessarily by choice,
02:07has to enter, but enters,
02:09and then hopefully goes down to the next station,
02:13possibly in remission if not healed.
02:15So, on this metaphor of the journey,
02:17on the wagons of the subway,
02:19you know that our subway is an object of art,
02:22it occurred to us, discussing with Professor Gaeta,
02:26to change the wagons,
02:29which are our emergency rooms,
02:32in which the patients must necessarily stay,
02:35in the hope that they will come out soon and well,
02:37and we used this very complex approach,
02:40which required an interaction between patients,
02:44the students of the Academy of the School of Decoration,
02:47our psychologists,
02:50to pull out these images,
02:52at most abstract,
02:54which now adorn all the rooms
02:56of our department of management,
02:58there is also an outside, of course,
03:00including the ceilings,
03:02because a healthy person
03:04hardly comes to mind
03:06to think that one who is in bed
03:08most of the hours of the day
03:10looks at the ceiling.
03:12Each room, thanks to the Academy,
03:14to its students, to the School of Decoration,
03:16has a different ceiling
03:18in which, precisely because the choice was
03:21by the artists,
03:24for abstract reasons,
03:26he can see what he wants,
03:28so he can imagine
03:31in a more adequate way
03:33the journey he will have to make
03:35until he is dismissed.
03:37One of the things that struck me
03:39was exactly this ceiling,
03:41because some patients told me,
03:43but they said it in a much more
03:46extensive way
03:48to our psychologists of the department,
03:51that he would have wanted,
03:53because he knew that more often
03:55our patients come in,
03:57then they are dismissed,
03:59to change the room every time
04:01to see them all, which is a nice thing.
04:03Today, fortunately, the scenario
04:05has completely changed,
04:07because while in the case of failure
04:09of the first line of therapy,
04:11usually another plant is used,
04:13an autologous plant of stem cells,
04:15which is still an option,
04:17but now we have the possibility
04:19to treat these patients
04:21in the subsequent lines to the first
04:23with very new drugs,
04:25which, in addition to the papers,
04:27are changing the scenario.
04:29The drugs that are changing it
04:31are those that are technically called
04:33bispecific antibodies,
04:35which are actually drugs
04:37that control the lymphocytes
04:39of the patient against the lymphoma,
04:41and they are revolutionizing the scenario
04:43and there are already studies
04:45that hopefully,
04:47if concluded positively,
04:49I am convinced,
04:51will lead to bispecific antibodies
04:53in the first line of treatment,
04:55therefore with the idea of healing
04:57already from the first line
04:59the largest possible number of patients
05:01with aggressive lymphoma.